Exelixis vs Neurocrine Biosciences
EXEL and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXEL and NBIX compare
Exelixis is the larger company, worth 1.2 times as much as Neurocrine Biosciences ($17.2B against $14.9B).
On earnings, Exelixis is cheaper: it trades at 20.8× trailing earnings, against 21.4× for Neurocrine Biosciences.
Neurocrine Biosciences grew revenue faster over the last twelve months (34.4% versus 9.1% for Exelixis).
Exelixis keeps more of each dollar of sales as profit, with a net margin of 35.5% compared with 20.9% at Neurocrine Biosciences.
Neurocrine Biosciences scores higher on the StockData Score (19 against 17 for Exelixis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXEL | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $17.2B | $14.9B |
| Share price | $69.39 | $146.10 |
| Change, 1 year | 76.0% | 5.9% |
| Change, 5 years | 258% | 56.7% |
| Beta (5Y) | 0.74 | 0.49 |
| Employees | 1,077 | 1,800 |
| StockData Score | ||
| Total score | 17 | 19 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 6 (better) | 5 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.8× (better) | 21.4× |
| P/S | 6.9× | 4.4× (better) |
| P/B | 9.4× | 4.0× (better) |
| EV/EBITDA | 15.8× (better) | 18.2× |
| P/FCF | 14.8× (better) | 17.1× |
| PEG | 0.29 (better) | 0.49 |
| FCF yield | 6.8% (better) | 5.9% |
| Fair value | $64.67 | $177.51 |
| Margin of safety | −7.3% | 17.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.1% | 34.4% (better) |
| Revenue growth, 5Y average | 18.6% | 22.3% (better) |
| Net income growth (TTM) | 30.6% | 103% (better) |
| EPS growth (TTM) | 40.9% | 102% (better) |
| EPS growth, 5Y average | 51.4% (better) | 2.3% |
| Profitability | ||
| Gross margin | 96.3% | 98.0% (better) |
| Operating margin | 40.2% (better) | 23.6% |
| Net margin | 35.5% (better) | 20.9% |
| FCF margin | 46.5% (better) | 25.8% |
| Return on equity | 44.3% (better) | 22.1% |
| Return on invested capital | 75.0% (better) | 23.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.21 (better) | 1.87 |
| Altman Z-score | 17.78 (better) | 6.83 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Buyback yield | 7.3% (better) | −0.84% |
| Shareholder yield | 7.3% (better) | −0.84% |
| Ownership | ||
| Held by institutions | 105% | 99.5% |
| Held by insiders | 9.7% | 1.2% |
| Insider net buying, 12 months | −$41.1M (better) | −$77.9M |
| Short interest, % of float | 12.6% | 5.8% |
Go deeper
- EXEL stock overview
- EXEL income statement
- EXEL valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.